RE:RE:Campbell - Valuation ComparisonCasey has already committed to getting out and telling Viemed's story to the investor community once the split is done. They have a really good story to tell as the Viemed division is growing at an aggressive rate organically already with Casey mentioning the potential for some acquisitions. I don't think the latter is important to Viemed's growth strategy - note they grew patient count by 10% last quarter which is 40% plus annual growth - the market will love this story and if you project longer than a quarter, you will see Viemed will have revenues and EBITDA comparable to PHM (including Apparo today). So the 5x multiple for Viemed is quite realistic over the next year or so. As for Apparo, another good story with positive EBITDA and lots of growth potential with an acquisition strategy. Greg has already demonstrated his ability to integrate companies quickly including capturing synergies and operating cost reductions. He also demonstrated an acquisition with a one year pay back. With this track record, Apparo has lots of opportunity to grow as well. Not sure of Greg's plans to tell his story to the investor community however it would seem to be a reasonable path to take given Greg and Casey are likely having many executive strategy discussions. I also like the potential for a sale with Apparo as this would realize big gains for shareholders within a reasonable period. Their CFO has a history of selling companies so keep this in mind as well. IMO - both companies have 5x upward market valuations, but don't expect this to occur over the next few months. A long term investor should take at least a one year view on these two investments. In the meantime, let the short traders have their fun helping us get rid of the weak hands.